In Cleveland and Moscow, researchers found freshly-manufactured T-cells showed faster reduction of tumor burden than cryopreserved cells, but uncertainty remains about what the clearance process for the technology will be at the US FDA.

Provention Bio’s teplizumab, a potentially game-changing treatment for preventing or delaying type 1 diabetes, is one of three investigational products to be newly accepted onto the European Medicines Agency’s popular priority medicines scheme.

This week's announcements include two CEO resignations at Nordic Nanovector and Verona Pharma, new CEOs at DalCor Pharmaceuticals and PureTech Health, new CMOs at Medigene, Argenx, Pneuma Respiratory and ReNeuron, plus board appointments.

Now providing seed and venture funding for some of its start-ups, University of Maryland's tech transfer has expanded its capabilities in recent years. Plus, our monthly roundup of private/public-sector transactions.